Mirum Pharmaceuticals, Inc.
NASDAQMirum Pharmaceuticals reports Q2 results after the bell today with short sellers retreating but options traders hedging into the print. Short interest is elevated but moving in the right direction for longs. At 13.5% of the free float, the bearish overhang is real — yet that figure has dropped about 11% over the past month, with the most recent reading down another 3.4% in a single…
Snapshot as of 24 Aug 2026
Mirum Pharmaceuticals reports Q2 results after the bell today with short sellers retreating but options traders hedging into the print. Short interest is elevated but moving in the right direction for longs. At 13.5%…
Mirum Pharmaceuticals enters the post-earnings window with a sharply upgraded growth story — Q1 sales of $159.9M beat estimates by 7%, and management lifted full-year guidance to $660M–$680M, well above the consensus…
MIRM enters its May 6 Q1 earnings report with a substantial short position and a stock that just broke sharply higher — a combination that makes Thursday's release genuinely consequential for both sides of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MIRM — free to start on ORTEX.
Sign up for free →Open MIRM on ORTEX